Morgan Stanley assumed coverage on shares of CLEMENTIA PHARM (NASDAQ:CMTA) in a research note released on Monday morning. The firm issued an overweight rating and a $27.00 target price on the stock.

CLEMENTIA PHARM (NASDAQ:CMTA) opened at 16.75 on Monday. CLEMENTIA PHARM has a 52 week low of $15.05 and a 52 week high of $18.95. The company’s 50-day moving average price is $14.97 and its 200 day moving average price is $14.97. The company’s market capitalization is $511.33 million.

COPYRIGHT VIOLATION WARNING: This article was posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at


Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models.

Receive News & Ratings for CLEMENTIA PHARM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CLEMENTIA PHARM and related companies with Analyst Ratings Network's FREE daily email newsletter.